MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas. 2015

Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
1 Tibbi Genetik AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey .

BACKGROUND Myeloid differentiation primary response 88 (MYD88) is a common adaptor protein that is responsible for signaling from several receptors; mutations in this gene may play a role in the pathogenesis of lymphoma. OBJECTIVE We aimed to determine the MYD88 L265P mutation frequency, the level of MYD88 expression, and their associations with clinicopathological parameters in mature B-cell non-Hodgkin lymphomas (NHLs). METHODS A total of 68 patients were included in the study. The presence of the MYD88 L265P mutation was analyzed by real-time polymerase chain reaction and direct sequencing. MYD88 protein expression was evaluated by immunohistochemistry (IHC) using two different scoring systems. RESULTS MYD88 L265P mutation was present in eight (18.6%) diffuse large B-cell lymphoma (DLBCL) patients. We also observed a significant association between the loss of MYD88 expression and advanced stage in both mature B-cell NHL and DLBCL according to the first IHC scoring systems (p=0.015 and p=0.024, respectively). An association was also seen between MYD88 overexpression and low clinical risk in both mature B-cell NHL and DLBCL according to the second IHC scoring system (p=0.027 and p=0.024, respectively). CONCLUSIONS The L265P mutation may be helpful for understanding the pathogenesis of immune-privileged site-associated DLBCLs. The presence of the mutation, together with its protein overexpression, could also be used as a prognostic marker in advanced stage DLBCLs.

UI MeSH Term Description Entries
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D016403 Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation. Diffuse Large B-Cell Lymphoma,Diffuse, Large B-Cell, Lymphoma,Histiocytic Lymphoma, Diffuse,Lymphoma, Histiocytic, Diffuse,Diffuse Large-Cell Lymphoma,Histiocytic Lymphoma,Large Lymphoid Lymphoma, Diffuse,Large-Cell Lymphoma, Diffuse,Lymphoma, Diffuse Large-Cell,Lymphoma, Histiocytic,Lymphoma, Large Cell, Diffuse,Lymphoma, Large Lymphoid, Diffuse,Lymphoma, Large-Cell, Diffuse,Diffuse Histiocytic Lymphoma,Diffuse Histiocytic Lymphomas,Diffuse Large B Cell Lymphoma,Diffuse Large Cell Lymphoma,Diffuse Large-Cell Lymphomas,Histiocytic Lymphomas,Large Cell Lymphoma, Diffuse,Lymphoma, Diffuse Histiocytic,Lymphoma, Diffuse Large Cell
D053594 Myeloid Differentiation Factor 88 An intracellular signaling adaptor protein that plays a role in TOLL-LIKE RECEPTOR and INTERLEUKIN 1 RECEPTORS signal transduction. It forms a signaling complex with the activated cell surface receptors and members of the IRAK KINASES. MyD88 Protein,TLR Signal Adaptor Protein MyD88,Toll-Like Receptor Signal Adaptor Protein MyD88,Toll Like Receptor Signal Adaptor Protein MyD88
D056726 Genetic Association Studies The analysis of a sequence such as a region of a chromosome, a haplotype, a gene, or an allele for its involvement in controlling the phenotype of a specific trait, metabolic pathway, or disease. Candidate Gene Identification,Candidate Gene Analysis,Candidate Gene Association Studies,Candidate Gene Association Study,Gene Discovery,Genotype-Phenotype Association,Genotype-Phenotype Associations,Genotype-Phenotype Correlation,Genotype-Phenotype Correlations,Analyses, Candidate Gene,Analysis, Candidate Gene,Association Studies, Genetic,Association Study, Genetic,Association, Genotype-Phenotype,Associations, Genotype-Phenotype,Candidate Gene Analyses,Correlation, Genotype-Phenotype,Correlations, Genotype-Phenotype,Discovery, Gene,Gene Analyses, Candidate,Gene Analysis, Candidate,Gene Identification, Candidate,Genetic Association Study,Genotype Phenotype Association,Genotype Phenotype Associations,Genotype Phenotype Correlation,Genotype Phenotype Correlations,Identification, Candidate Gene,Studies, Genetic Association,Study, Genetic Association
D060888 Real-Time Polymerase Chain Reaction Methods used for detecting the amplified DNA products from the polymerase chain reaction as they accumulate instead of at the end of the reaction. Kinetic Polymerase Chain Reaction,Quantitative Real-Time PCR,Quantitative Real-Time Polymerase Chain Reaction,Real-Time PCR,PCR, Quantitative Real-Time,PCR, Real-Time,PCRs, Quantitative Real-Time,PCRs, Real-Time,Quantitative Real Time PCR,Quantitative Real Time Polymerase Chain Reaction,Quantitative Real-Time PCRs,Real Time PCR,Real Time Polymerase Chain Reaction,Real-Time PCR, Quantitative,Real-Time PCRs,Real-Time PCRs, Quantitative

Related Publications

Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
February 2014, Zhongguo shi yan xue ye xue za zhi,
Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
September 2016, Blood research,
Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
July 2013, Human pathology,
Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
February 2014, Blood cancer journal,
Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
May 2015, The American journal of surgical pathology,
Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
January 1990, Hematological oncology,
Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
January 2019, Frontiers in oncology,
Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
November 2006, Human pathology,
Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
May 2024, Lancet (London, England),
Vildan Caner, and Nilay Sen Turk, and Ikbal Cansu Baris, and Gokhan Ozan Cetin, and Emre Tepeli, and Sibel Hacioglu, and Ismail Sari, and Sevil Zencir, and Mehmet Hilmi Dogu, and Gulseren Bagci, and Ali Keskin
February 2024, Medicine,
Copied contents to your clipboard!